Asani, Ben
Siedlecki, Jakob
Wertheimer, Christian
Liegl, Raffael
Wolf, Armin
Ohlmann, Andreas
Priglinger, Siegfried
Priglinger, Claudia
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 2 September 2021
Accepted: 25 February 2022
First Online: 25 March 2022
Declarations
:
: Not applicable.
: Not applicable.
: Christian Wertheimer, Raffael Liegl, Andreas Ohlman and Claudia Priglinger declare that they have no financial or competing interests.Ben Asani has received speaker fees from Novartis Pharma GmbH. Jakob Siedlecki receives speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis Pharma GmbH, Bayer AG, Pharm-Allergan GmbH, Oculentis OSD Medical GmbH. Consultant: Bayer AG, Novartis Pharma GmbH, Pharm-Allergan GmbH. Travel reimbursement: Oertli AG. Armin Wolf receives fees for lectures/consulting or research funding from Novartis Pharma GmbH; Bayer Healthcare AG; Alimera; Allergan; Oertli Instrumente AG; Roche and Appellis. Siegfried Priglinger receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Geuder, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss and research funding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss.